quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:40:00·3d
PRRelease
Black Diamond Therapeutics Inc. logo

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

BDTX· Black Diamond Therapeutics Inc.
Health Care
Original source

Companies

  • BDTX
    Black Diamond Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 3UpdateGuggenheim-
  • Nov 18UpdatePiper Sandler$9.00
  • Oct 16UpdateStifel$8.00
  • Sep 4UpdateGuggenheim$8.00
  • Jul 1UpdateRaymond James$11.00
  • Jul 31UpdateRaymond James$20.00

Related

  • INSIDER34d
    SEC Form 4 filed by Behbahani Ali
  • INSIDER34d
    SEC Form 4 filed by Raman Prakash
  • SEC38d
    SEC Form S-8 filed by Black Diamond Therapeutics Inc.
  • SEC38d
    SEC Form 10-K filed by Black Diamond Therapeutics Inc.
  • SEC38d
    Black Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR38d
    Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
  • PR52d
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
  • PR71d
    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022